French AFU Cancer Committee Guidelines – Update 2024–2026: Prostate cancer – Diagnosis and management of localised disease - 22/11/24

Doi : 10.1016/j.fjurol.2024.102717

Guillaume Ploussard ^a,^e,^⁎ , Michaël Baboudjian ^r, Eric Barret ^c, Laurent Brureau ^d, Gaëlle Fiard ^h, Gaëlle Fromont ^p, Jonathan Olivier ⁱ, Charles Dariane ^f,^g, Romain Mathieu ^b, François Rozet ^c, Arthur Peyrottes ^q, Guilhem Roubaud ^o, Raphaële Renard-Penna ^j, Paul Sargos ^m, Stéphane Supiot ^k, Léa Turpin ^l, Morgan Rouprêt ⁿ
Comité de Cancérologie de l’Association Française d’Urologie, Groupe Prostate, Maison de l’Urologie^s
^a Department of Urology, La Croix du Sud Hospital, Quint-Fonsegrives, France
^b Department of Urology, CHU de Rennes, Rennes, France
^c Department of Urology, Institut Mutualiste Montsouris, Paris, France
^d Department of Urology, CHU de Pointe-à-Pitre, University of Antilles, University of Rennes, Inserm, EHESP, Institut de Recherche en Santé, Environnement et Travail (Irset), UMR_S 1085, 97110 Pointe-à-Pitre, Guadeloupe
^e Department of Radiotherapy, Institut Curie, Paris, France
^f Department of Urology, Hôpital européen Georges-Pompidou, AP–HP, Paris, France
^g Paris University, U1151 Inserm, INEM, Necker, Paris, France
^h Department of Urology, Grenoble Alpes University Hospital, Université Grenoble Alpes, CNRS, Grenoble INP, TIMC-IMAG, Grenoble, France
ⁱ Department of Urology, CHRU de Lille, Lille, France
^j Sorbonne University, AP–HP, Radiology, Pitié-Salpêtrière Hospital, 75013 Paris, France
^k Radiotherapy Department, Institut de Cancérologie de l’Ouest, Saint-Herblain, France
^l Nuclear Medicine Department, Hôpital Foch, Suresnes, France
^m Department of Radiotherapy, Institut Bergonié, 33000 Bordeaux, France
ⁿ Sorbonne University, GRC 5 Predictive Onco-Uro, AP–HP, Urology, Pitié-Salpêtrière Hospital, 75013 Paris, France
^o Department of Medical Oncology, Institut Bergonié, 33000 Bordeaux, France
^p Department of Pathology, CHRU, 37000 Tours, France
^q Department of Urology, CHU Saint-Louis, Paris, France
^r Department of Urology, AP–HM Marseille, Marseille, France
^s 11, rue Viète, 75017 Paris, France

^⁎Corresponding author at: La Croix du Sud Hospital, 52 bis, chemin de Ribaute, 31130 Quint-Fonsegrives, France.La Croix du Sud Hospital52 bis, chemin de RibauteQuint-Fonsegrives31130France

Abstract

Objective

The aim of the Oncology Committee of the French Urology Association is to propose updated recommendations for the diagnosis and management of localized prostate cancer (PCa).

Methods

A systematic review of the literature from 2022 to 2024 was conducted by the CCAFU on the elements of diagnosis and therapeutic management of localized PCa, evaluating references with their level of evidence.

Results

The recommendations set out the genetics, epidemiology and diagnostic methods of PCa, as well as the concepts of screening and early detection. MRI, the reference imaging test for localized cancer, is recommended before prostate biopsies are performed. Molecular imaging is an option for disease staging. Performing biopsies via the transperineal route reduces the risk of infection. Active surveillance is the standard treatment for tumours with a low risk of progression. Therapeutic methods are described in detail, and recommended according to the clinical situation.

Conclusion

This update of French recommendations should help to improve the management of localized PCa.

Le texte complet de cet article est disponible en PDF.

Keywords : Prostate cancer, Diagnosis, Treatment, Guidelines, Screening

Plan

Export

Vol 34 - N° 12

Article 102717- novembre 2024 Retour au numéro

Article précédent

French AFU Cancer Committee Guidelines – Update 2024–2026: Management of kidney cancer
Pierre Bigot, Romain Boissier, Zine-Eddine Khene, Laurence Albigès, Jean-Christophe Bernhard, Jean-Michel Correas, Stéphane De Vergie, Nicolas Doumerc, Matthieu Ferragu, Alexandre Ingels, Gaëlle Margue, Idir Ouzaïd, Caroline Pettenati, Nathalie Rioux-Leclercq, Paul Sargos, Thibaut Waeckel, Philippe Barthelemy, Morgan Rouprêt

| Article suivant

French AFU Cancer Committee Guidelines – Update 2024–2026: Prostate cancer – Management of metastatic disease and castration resistance
Guillaume Ploussard, Charles Dariane, Romain Mathieu, Michaël Baboudjian, Eric Barret, Laurent Brureau, Gaëlle Fiard, Gaëlle Fromont, Jonathan Olivier, François Rozet, Arthur Peyrottes, Raphaële Renard-Penna, Paul Sargos, Stéphane Supiot, Léa Turpin, Guilhem Roubaud, Morgan Rouprêt, Comité de Cancérologie de l’Association Française d’Urologie, Groupe Prostate, Maison de l’Urologie

Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.

Déjà abonné à cette revue ?

connectez-vous ou créez un compte

French AFU Cancer Committee Guidelines – Update 2024–2026: Prostate cancer – Diagnosis and management of localised disease - 22/11/24

Abstract

Objective

Methods

Results

Conclusion

Plan

Export citations

Fichier

Contenu

Accès rapides

Mon compte

Aide & support

Plateformes Elsevier Masson

Déclaration CNIL